Cardiac Diagnostics System for Biomarkers in whole Blood
Acute myocardial infarction (AMI) is one of the major diseases that threaten human health.
In recent years, the incidence of AMI has increased year over year. Early diagnosis of AMI is conducive to early diagnosis and treatment which can improve the prognosis of AMI patients. Highly sensitive cardiac troponin (hs-cTn) can measure cTn concentration, even at low levels, with high accuracy, which has important clinical significance for the diagnosis and risk stratification of AMI and is a specific indicator for the diagnosis of AMI. According to the guidelines, if the hs-cTn results have not increased in patients with chest pain on admission, blood samples should be drawn again at 1-4 hour intervals and compared to the first results, if the results have increased by more than 30%, the diagnosis of AMI should be considered.
In addition, elevated troponin has been shown to be associated with an increased risk of adverse events in patients with AMI. However, electrochemiluminescence (ECG) is currently the most commonly used method of detecting troponin. The method is currently detected on a large biochemical analyzer, and the time required to detect hs-cTn is long, which means that it is impossible to perform a bedside inspection and count against the rapid diagnosis of AMI. The disadvantage of the traditional point-of-care (POCT) screening method is the use of serum, which is not possible in pre-hospital first aid. Therefore, the search for SPECTANTS technology based on whole blood is more valuable.
Facts on Cardiovascular Diseases (CVD)
- 17.9 million people die each year from Cardiovascular diseases (CVD), an estimated 31% of all deaths worldwide. (about 49,000 a day) Among these, about 85% deaths are caused due to heart attack.
- A heavy economic burden:
Total annual costs of CVD are expected to reach $1.1 trillion by 2035, with direct medical cost projected to reach $748.7 billion and indirect costs estimated to reach $368 billion.*
* Sources: Global Atlas on Cardiovascular Disease Prevention and Control. Mendis S, Puska P, Norrving B editors. World Health Organization/World Heart Federation/World Stroke Organization/, Geneva 2017.
Fourth Universal Definition of Myocardial Infarction AHA (2018)
Key Role of Cardiac Troponin in Modern Cardiology
Elevation of Cardiac Troponin
A criteria of myocardial infarction
Levels of Cardiac Troponin
high prognostic value.
There is no lower level of Cardiac Troponin in the blood
Guidelines recommendation
All guidelines recommend to measure the concentration of Cardiac troponin for Acute coronary syndrome patients.
Our Vision
Our strategic focus
The most highly ranked attributes Spectants to CVD is associated with whole blood analysis, falls into five themes:
- Real Time analysis biomarkers in blood.
- Lebel free analysis.
- High Throughput Screening (HTS).
- Maximizing efficiency by using minimal amount of blood, and AI learning algorithm.
- Cost-effective diagnostic and mobile battery charged unit.
Our strategic goal
Real time analysis of the essential biomarkers in blood for CVD patients.
To reduce emergency room and private clinic’s loads.
An AI assisted self-learning algorithm, managed and supervised by MD on site or at a distance.
Cost effective analysis for patient and insurance.
A noninvasive portable blood analysis device, to be diploid always and everywhere.
Evolution of our research and Milestones
2000
Publishing No low threshold of Troponin in blood
2006
Ai Algorithm to evolve in silico Peptide Aptamer that bind to target proteins
2011
Cutting short antibodies against troponin molecules doesn’t solve the problem of the sensitivity of electrical sensor (Nano Letters 2012, 12, 1, 7-12)
2019
Establishing Spectants SAS Cardio Biomarkers Diagnostics
2020
Peptide Aptamers to bind Cardiac Troponin in blood
1st Milestone
2021
Proof of concept
2022
Cardiac Point of Care developing and design
2nd Milestone
2023
Point of Care Prototype / third party validation
3rd Milestone
2024
CE / FDA approval